Executive Summary

USD 857.2 Million in 2025, the Urine Bags Market is expected to grow at a CAGR of 9.41% to reach USD 2,110 Million by 2035. Growth over the 2025-2035 window reflects extended-wear catheterization protocols in bedridden and post-surgical patients, alongside the shift of continence care into home and long-term care settings. Most bedside and leg bags clear the US FDA through the 510(k) pathway as Class I or II devices, and Medicare coverage rules such as CMS Local Coverage Determination L33803 assign CMS reimbursement codes and CPT/HCPCS A4357 (bedside bags) and A4358/A5112 (leg bags) that set quantity limits and anchor recurring per-patient replacement volume in the largest single market.

North America led with a 35.0% share, ahead of Europe at 27.0% and Asia Pacific at 25.0%. Bedside Bags held the leading position among product types at a 35% share in 2024, and Polyvinyl Chloride (PVC) accounted for 60% of material demand the same year. Reimbursement scope and CMS quantity caps under DME benefit rules constrain replacement frequency in the largest market. In Europe, EU MDR and IVDR reclassification of sterile Class I bags is raising compliance cost, compounded by HTA bodies’ scrutiny of incremental clinical value in reimbursement dossiers. Registration under India’s CDSCO and volume-based procurement tenders in China shape entry terms across the rest of Asia Pacific. Competitive intensity centers on manufacturing scale, tender participation and catheter-care bundling relationships with hospital and homecare distributors.

Key Takeaways

• A CAGR of 9.41% carries the market from USD 857.19 Million in 2025 to USD 2,110.00 Million in 2035.
• Hospital is the largest application category.
• On product type, Bedside Bags holds 0.3%.
• 35.0% of 2025 revenue was earned in North America.
• 10 suppliers are profiled.

Market Definition and Scope

The Urine Bags Market covers disposable and reusable urinary drainage collection systems, spanning leg bags, bedside drainage bags, pediatric urine bags and specialty formats, manufactured in PVC, polyethylene and silicone across capacity tiers from 0-500 mL pediatric and ambulatory units to more than 2000 mL high-volume ICU and bariatric bags. Products are used with indwelling catheters, condom catheters and suprapubic tubes in hospital, ambulatory surgical center and homecare settings, and are sold through hospital procurement, DME suppliers and retail pharmacy channels.

Excluded are the indwelling and intermittent catheters themselves, external condom catheter devices absent a collection reservoir, ostomy and fecal collection pouches, and colostomy or urostomy stoma appliances, all of which sit in adjacent device categories with distinct regulatory classifications.

Market Trends

Extended-wear catheterization is shifting demand toward higher-capacity bedside bags

Bedridden and post-surgical inpatients increasingly use indwelling catheters over longer stays, pushing volume toward 1001-2000 mL and above-2000 mL bedside and high-volume ICU bags rather than smaller ambulatory formats. The CDC’s National Healthcare Safety Network tracks catheter-associated urinary tract infection rates as the clinical rationale for lower-frequency bag changes, and CMS’s L33803 coverage rule, last revised April 2026, caps bedside bags billed under HCPCS code A4357 at two per month, fixing replacement cadence and making capacity tier, not unit count, the lever suppliers compete on. Most bedside and high-volume bags reach market as FDA 510(k)-exempt Class I devices, which keeps new capacity tiers moving into hospitals and long-term care facilities faster than higher-classification urology hardware. Demand for larger-format bags is expected to outpace smaller tiers through 2035.

DEHP-free PVC formulations are gaining share within the dominant material base

PVC held 60% of material demand in 2024, but plasticizer-safety scrutiny is pushing manufacturers toward DEHP-free PVC and polyethylene alternatives, particularly for pediatric and long-wear indications. This affects pediatric urine bag producers most directly, given prolonged skin and fluid contact in that segment. Export-oriented manufacturers continue registering standard PVC lines with India’s CDSCO under the Medical Device Rules, since cost and moldability advantages hold that base in tender-driven markets even as DEHP-free formulations gain ground elsewhere. Material substitution is incremental rather than wholesale, but the DEHP-free sub-tier is set to grow faster than standard PVC through the forecast period.

EU MDR reclassification is reshaping the competitive field for sterile class I bags

Regulation (EU) 2023/607 requires sterile class I urine bags, previously self-certified under the MDD, to obtain notified body certification, with formal applications due by May 2024 and the extended transition running to December 2028. Smaller European manufacturers unable to secure notified body capacity face market exit or consolidation, concentrating share among suppliers with existing EU MDR and IVDR certification. National HTA bodies factor that certification status into hospital tender qualification, so a lapsed notified body file can cost a supplier reimbursed volume before any formal enforcement action follows.

Growth Drivers and Restraints

Extended catheterization protocols in bedridden and post-surgical care are lifting replacement volume

Longer indwelling catheter dwell times in bedridden, ICU and post-surgical patients increase per-patient bag consumption, particularly in the 1001-2000 mL and above-2000 mL capacity tiers used for extended or continuous drainage. The CDC’s National Healthcare Safety Network surveillance data on catheter-associated urinary tract infections underpins hospital protocols that favor closed, less-frequently-changed drainage systems over routine bag swaps. CMS’s L33803 determination, revised effective April 2026, formalizes the resulting replacement cycle by capping bedside bags (HCPCS code A4357) at two per month and leg bags (A5112) at one per three months under Medicare’s DMEPOS benefit, fixing a reimbursement-anchored purchase pattern across all four DME MAC jurisdictions. Hospitals and long-term care facilities in the United States, the largest single national market inside North America’s 35.0% regional share, absorb the bulk of this volume, with bedside and high-capacity formats gaining share over standard leg bags as a result.

Homecare and outpatient shift is expanding leg bag and ambulatory demand

Care delivery is moving toward ambulatory surgical centers, physician clinics and home settings for catheter management, a shift that favors compact, discreet leg bags over bedside formats for mobile patients. CMS’s L33803 rule assigns separate HCPCS coverage for vinyl (A4358) and latex (A5112) leg bags apart from bedside bags, permitting payment for one or the other but not both, which structures homecare procurement patterns. Newer leg bags with fill-level sensors for remote monitoring must route usage data through systems compliant with HIPAA in the United States and GDPR in Europe, a compliance layer that slows adoption of connected formats relative to standard bags. Clinics and urology practices, a distinct application segment from hospitals in this market’s own segmentation, remain the primary channel absorbing the shift as outpatient catheterization volume grows through 2035.

Medicare quantity limits cap replacement frequency and constrain revenue per patient

L33803’s fixed monthly and quarterly quantity caps, plus its denial of leg bags as not reasonable and necessary for bedridden beneficiaries, place a structural ceiling on unit volume per Medicare beneficiary regardless of underlying clinical need. Most urine bags reach market as Class I devices without FDA 510(k) premarket clearance, so entry barriers sit almost entirely on the reimbursement side rather than on device approval, concentrating competitive pressure on capacity-tier upgrades instead of unit count. Extension tubing (A4331) is separately bundled into several HCPCS code allowances rather than billed independently, further compressing incremental revenue per drainage system sold.

EU MDR recertification cost is a structural burden on legacy sterile bag lines

Sterile class I and class IIa urine bags, previously exempt from notified body review under the MDD, now require full notified body conformity assessment under Regulation (EU) 2023/607, part of the broader EU MDR and IVDR transition, conditional on a formal application lodged by 26 May 2024 and a signed agreement by 26 September 2024, with the extended transition ending 31 December 2028. Smaller European manufacturers face disproportionate compliance cost relative to product volume, and national HTA bodies layer further reimbursement review on top of the CE mark before a recertified bag reaches hospital tenders. Europe’s 27.0% regional share is the segment most exposed to this recertification bottleneck through the transition deadline.

Segment Analysis

Capacity

• 0-500 mL – A small-volume urine collection bag typically used for short-duration or pediatric drainage where frequent, low-volume output monitoring is needed
• Leg Bags

• Thigh Bags
• Calf/Shin Bags
• Pediatric Bags
• 501-1000 mL – A mid-sized urine bag used for standard adult catheterization in general ward and short-term post-operative drainage settings
• Leg Bags

• Thigh Bags
• Calf/Shin Bags
• Bedside Drainage Bags

• Drainable Bags
• Non-Drainable Bags
• 1001-2000 mL – A larger-capacity urine bag commonly used for extended-wear catheterization, bedridden patients, and overnight or continuous drainage needs
• Bedside Drainage Bags

• Drainable Bags
• Non-Drainable Bags
• Overnight/Night Bags
• More than 2000 mL – A high-capacity urine bag designed for extended collection intervals, intensive care use, or patients with high urine output requiring less frequent emptying

• Bariatric Bags
• High-Volume ICU/Bedside Bags
• Others – Non-standard or specialty capacity urine bags, including custom-sized or leg-worn ambulatory bags, that fall outside the common volume tiers

Application

• Hospital (largest) – An inpatient or acute-care facility where urine bags are used on catheterized patients for post-surgical, critical, or long-term bedside urinary drainage and monitoring

• Government Hospitals
• Private Hospitals
• Clinic – An outpatient care setting where urine bags are used for short-term catheterization, urine sample collection, and minor urological procedures

• Physician Clinics
• Urology Clinics
• Ambulatory Surgical Centers

By Product Type

• Leg Bags – A compact drainage bag strapped discreetly to the thigh or calf, worn under clothing by ambulatory patients using an indwelling or condom catheter

• Thigh Bags
• Below-Knee Bags
• Bedside Bags (largest, 0.35% share) – A larger-capacity drainage bag hung on a bed frame or floor stand for overnight or immobile catheterized patients in hospitals and home care

• Sterile Bedside Bags
• Non-Sterile Bedside Bags
• Pediatric Urine Bags – A small adhesive collection bag designed for infants and children to gather urine samples or manage drainage without catheterization

• Male Pediatric Urine Bags
• Female Pediatric Urine Bags
• Others – Specialty urine collection devices such as belly bags, thigh-strap variants, and disposable collection pouches that fall outside standard leg, bedside, or pediatric designs

By Material

• Polyvinyl Chloride (PVC) (largest, 0.6% share) – A flexible plastic polymer molded into transparent, cost-effective drainage bags with tubing, valves, and connectors for collecting and storing urine

• Standard PVC
• DEHP-free PVC
• Polyethylene (PE) – A lightweight, chemically inert thermoplastic used to form soft, puncture-resistant urine bag pouches favored for latex-free and lower-toxicity collection systems

• Low-Density Polyethylene (LDPE)
• High-Density Polyethylene (HDPE)

• Silicone – A biocompatible elastomer used for urine bag components and catheter-connecting tubing where extended wear, skin contact, or hypoallergenic properties are required
• Others – Alternative materials such as polyurethane, EVA, or biodegradable polymers used in specialty or niche urine collection bag designs

• Latex
• Rubber

Segment Analysis

By Product Type

Bedside Bags led the product-type category with 35.0% of revenue in 2025. Hospitals procure them in bulk for immobile and post-surgical inpatients, where sterile, high-capacity drainage sets are matched to bed-frame or floor-stand mounts and changed on a fixed schedule under infection-control protocols. Leg Bags are the fastest-growing format. Their strap-on profile lets ambulatory catheter users work, travel and sleep without a visible collection set, a fit that outpatient and homecare programs favor as more catheterization shifts away from the inpatient ward.

By Material

Polyvinyl chloride accounted for 60.0% of material demand in 2025, the largest share on the axis. PVC molds into a clear, flexible, low-cost bag body that tolerates the tubing and valve connections a urine bag needs, and its supply chain is the most established of any polymer used in the category. Polyethylene is growing fastest. Hospitals moving away from DEHP-plasticized components for neonatal and long-wear indications are pulling demand toward PE and silicone parts, which carry a lower leaching and hypersensitivity profile.

By End User

Hospital is the leading application, accounting for the greater share of use in 2025, since it manages the bulk of catheterized inpatients across post-surgical recovery, critical care and long-term bedside drainage under continuous nursing supervision. Clinics show the faster growth path. Physician clinics, urology clinics and ambulatory surgical centers are absorbing more short-term catheterization and urine-sample collection as procedures move out of the inpatient setting, reinforced by wider use of disposable, portable collection formats in outpatient and temporary-care settings.

Regional Analysis

North America held 35.0% of the urine bags market in 2025, the largest of the three regions reported. Wellspect HealthCare puts the population living with severe urinary incontinence above 13 million Americans, a base that anchors sustained catheter and drainage-bag consumption across US hospital and home-care channels. Most bedside and leg bags qualify as FDA Class I devices exempt from 510(k) premarket review, but CDC guidance on catheter-associated urinary tract infection prevention still sets the clinical specification hospitals procure against, and CMS reimbursement codes under CPT/HCPCS anchor the Medicare and Medicaid claim cycles that keep bulk purchasing inside IDN and GPO contracts rather than retail sale.

Europe accounted for a 27.0% share in 2025. Urine bags sold into the bloc fall under the EU Medical Device Regulation as Class I devices, and the years since its application have pushed smaller national manufacturers toward third-party notified-body support or exit, consolidating supply toward manufacturers able to carry the compliance file at scale. Health technology assessment bodies feed into the national tender systems that award multi-year hospital-supply contracts in markets such as Germany and France, where unit price rather than material innovation wins the bid and keeps PVC-based bedside bags the default over costlier alternatives. The UK’s post-Brexit UKCA route runs in parallel, adding a second compliance track for suppliers targeting British hospital trusts.

Asia Pacific closed 2025 with a 25.0% share. China’s volume-based procurement program for medical consumables has pulled hospital tender pricing down on standardized items including catheter drainage sets, favoring domestic manufacturers with the scale to bid at reduced margins. India’s expanding private-hospital network is building out a parallel, less price-controlled channel, and devices entering it clear registration through the CDSCO rather than through a Western regulator first. Japan’s PMDA clearance pathway and Australia’s therapeutic-goods listing add separate, smaller regulatory gateways that most entrants clear only after establishing volume in China and India.

Competitive Landscape

Competitive Landscape

The urine bags market is led by a group of established medical device manufacturers rather than by a single dominant supplier. Competition centers on manufacturing scale and quality record, since bedside and leg bags are high-volume, low-unit-cost disposables won mostly on GPO and IDN contract pricing, consistent regulatory clearance, and the ability to hold multi-country distribution without stock-outs. Existing hospital-supply relationships and tender awards create a consumable lock-in that favors incumbents over new entrants. Smaller players compete on speed to quote for standing hospital orders rather than on breadth of catalog. Named participants include Bard, Teleflex, Coloplast A/S, B. Braun Medical, Medline, Covidien, Flexicare Medical, Apexmed, Coopetition Med and Urocare. Coloplast A/S and B. Braun Medical carry broader continence-care portfolios that let them bundle bags with catheters and irrigation lines into single hospital contracts, while Medline and Teleflex compete chiefly on US distribution reach and private-label supply agreements. Regional specialists such as Flexicare Medical and Urocare hold narrower ranges but compete on price within specific national tender processes rather than on portfolio breadth.

Strategic Outlook

Strategic Outlook

The clearest whitespace sits in outpatient and homecare drainage, where leg bags and disposable, portable formats stand to gain as more catheterization moves out of the inpatient ward. Clinics and ambulatory surgical centers are best placed to capture it, provided manufacturers push DEHP-free and latex-free materials fast enough to meet hospital procurement standards rather than lag behind them.

By 2035, expect the product mix to keep tilting from PVC bedside bags toward polyethylene and silicone components, and toward a more even split between hospital and clinic buyers as ambulatory care expands.

Urine Bags Market Report Scope